Preferred Label : Bexarotene;
MeSH definition : A tetrahydronaphthalene derivative and RETINOID X RECEPTOR antagonist that is used
in the treatment of CUTANEOUS T-CELL LYMPHOMA.; A rexinoid (an RXR-binding ligand), tetrahydronaphthalene derivative and RETINOID
X RECEPTOR antagonist that is used in the treatment of CUTANEOUS T-CELL LYMPHOMA.;
MeSH synonym : 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid;
MeSH hyponym : LGD-1069; LGD1069;
UNII : A61RXM4375;
InChIKey : InChIKey: NAVMQTYZDKMPEU-UHFFFAOYSA-N;
Origin ID : D000077610;
UMLS CUI : C0765273;
ATC code(s)
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
A tetrahydronaphthalene derivative and RETINOID X RECEPTOR antagonist that is used
in the treatment of CUTANEOUS T-CELL LYMPHOMA.
A rexinoid (an RXR-binding ligand), tetrahydronaphthalene derivative and RETINOID
X RECEPTOR antagonist that is used in the treatment of CUTANEOUS T-CELL LYMPHOMA.
http://www.meddispar.fr/Medicaments/TARGRETIN-75-B-100/(type)/letter/(value)/T/(cip)/3400936574793
2013
false
France
French
drug information
administration, oral
bexarotene
drug prescriptions
legislation, drug
continuity of patient care
Bexarotene
---
http://www.has-sante.fr/portail/jcms/c_1269694/targretin-bexarotene-retinoide
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-07/targretin_28032012_synthese_ct18885.pdf
2012
false
France
French
guidelines for drug use
bexarotene
anticarcinogenic agents
anticarcinogenic agents
administration, oral
lymphoma, T-cell, cutaneous
treatment outcome
hypothyroidism
dyslipidemias
neoplasm staging
insurance, health, reimbursement
Bexarotene
Bexarotene
---
https://www.ema.europa.eu/medicines/human/EPAR/Targretin
2012
false
United Kingdom
English
French
syndication feed
anticarcinogenic agents
lymphoma, T-cell, cutaneous
pregnancy
breast feeding
treatment outcome
drug evaluation
bexarotene
administration, oral
anticarcinogenic agents
Product containing precisely bexarotene 75 milligram/1 each conventional release oral
capsule (clinical drug)
drug evaluation
package leaflet
summary of product characteristics
Bexarotene
Bexarotene
---
http://www.has-sante.fr/portail/jcms/c_1241661/targretin
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-04/targretin_28032012_avis_ct118885.pdf
http://www.has-sante.fr/portail/jcms/c_574633/targretin
http://www.has-sante.fr/portail/jcms/c_399464/targretin-75mg-capsules-molles-flacon-de-100-capsules
2012
false
France
French
evaluation of the transparency committee
mycosis fungoides
insurance, health, reimbursement
administration, oral
lymphoma, T-cell, cutaneous
bexarotene
anticarcinogenic agents
treatment outcome
adult
aged
Product containing precisely bexarotene 75 milligram/1 each conventional release oral
capsule (clinical drug)
Bexarotene
Bexarotene
---